FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285803902> ?p ?o ?g. }

• W4285803902 endingPage "59" @default.
• W4285803902 startingPage "48" @default.
• W4285803902 abstract "Aim . To compare the clinical efficacy and influence on interferon (IFN) production / sensing of drugs with immunemediated antiviral effects, which potentiate type 1 (T1) immune responses, in the treatment of acute respiratory infections (ARI) in patients with allergic rhinitis. Materials and methods. 146 ARI patients with remission of seasonal allergic rhinitis were divided into 4 cohorts. In addition to symptomatic therapy, patients received either 2,000 IU of IFNγ in each nasal passage 5 times a day; or rectal suppositories containing 106 IU of IFN-α2b and antioxidants (AO) twice a day, and a gel with IFN-α2b and AO intranasally 3 times a day; or 400 mg of pidotimod per os twice a day; or 125 mg of tilorone per os on days 1, 2, 4, and 6. The severity of ARI was determined daily as the sum of 10-point scores for 15 symptoms. Serum concentrations of IFNα and IFNγ and the ability of blood cells to produce these cytokines ex vivo spontaneously and upon stimulation with Newcastle disease virus or phytohemagglutinin were studied using enzyme-linked immunosorbent assay (ELISA). The proportions of circulating lymphocytes expressing type I IFN receptor subunit 2 (CD118) or IFNγ receptor α-chain (CD119) were determined by flow cytometry. Results . ARI symptoms in all cohorts generally regressed in a similar way. However, from day 5 of the treatment, pidotimod relieved symptoms more effectively than other drugs. In patients treated with tilorone, the regression of ARI manifestations was delayed in the first two to three days, followed by rapid symptom reduction. An initial decrease in the induced production of IFNγ was found in patients treated with pidotimod, and a tendency to a decrease in this parameter was noted in other cohorts. The induced production of IFNγ after the treatment in all groups did not differ from that in healthy donors. No significant changes and differences in the proportions of CD118+ and CD119+ lymphocytes were found between the cohorts, except for a decrease in the number of CD118+ cells after the treatment with tilorone. In patients treated with IFN-α2b + AO, the proportions of CD119+ and CD118+ lymphocytes tended to increase slightly. Conclusion . Drugs that promote the development of T1 over T2 immune responses are a useful option for treating ARI in patients with allergic rhinitis." @default.
• W4285803902 created "2022-07-19" @default.
• W4285803902 creator A5008969368 @default.
• W4285803902 creator A5041048665 @default.
• W4285803902 creator A5044730303 @default.
• W4285803902 creator A5067389864 @default.
• W4285803902 creator A5072757294 @default.
• W4285803902 creator A5074586053 @default.
• W4285803902 date "2022-07-16" @default.
• W4285803902 modified "2023-09-27" @default.
• W4285803902 title "Interferons alpha and gamma, pidotimod, and tilorone in the treatment of acute respiratory infections in patients with allergic rhinitis: a prospective, cohort clinical and immunological study" @default.
• W4285803902 cites W1603804386 @default.
• W4285803902 cites W1967475015 @default.
• W4285803902 cites W1978149967 @default.
• W4285803902 cites W1986101280 @default.
• W4285803902 cites W2015037737 @default.
• W4285803902 cites W2018963759 @default.
• W4285803902 cites W2036250782 @default.
• W4285803902 cites W2050052221 @default.
• W4285803902 cites W2062019093 @default.
• W4285803902 cites W2073526502 @default.
• W4285803902 cites W2080062014 @default.
• W4285803902 cites W2081204822 @default.
• W4285803902 cites W2087459689 @default.
• W4285803902 cites W2092800788 @default.
• W4285803902 cites W2110456507 @default.
• W4285803902 cites W2111218879 @default.
• W4285803902 cites W2118859274 @default.
• W4285803902 cites W2129935236 @default.
• W4285803902 cites W2148810559 @default.
• W4285803902 cites W2155991561 @default.
• W4285803902 cites W2167017590 @default.
• W4285803902 cites W2728825901 @default.
• W4285803902 cites W2778305361 @default.
• W4285803902 cites W2904676327 @default.
• W4285803902 cites W2908905692 @default.
• W4285803902 cites W2978521189 @default.
• W4285803902 cites W3014641626 @default.
• W4285803902 cites W3021800073 @default.
• W4285803902 cites W3042190352 @default.
• W4285803902 cites W3047551068 @default.
• W4285803902 cites W3098787602 @default.
• W4285803902 cites W3131099803 @default.
• W4285803902 cites W3156406264 @default.
• W4285803902 cites W3174883815 @default.
• W4285803902 cites W4256661178 @default.
• W4285803902 doi "https://doi.org/10.20538/1682-0363-2022-2-48-59" @default.
• W4285803902 hasPublicationYear "2022" @default.
• W4285803902 type Work @default.
• W4285803902 citedByCount "0" @default.
• W4285803902 crossrefType "journal-article" @default.
• W4285803902 hasAuthorship W4285803902A5008969368 @default.
• W4285803902 hasAuthorship W4285803902A5041048665 @default.
• W4285803902 hasAuthorship W4285803902A5044730303 @default.
• W4285803902 hasAuthorship W4285803902A5067389864 @default.
• W4285803902 hasAuthorship W4285803902A5072757294 @default.
• W4285803902 hasAuthorship W4285803902A5074586053 @default.
• W4285803902 hasBestOaLocation W42858039021 @default.
• W4285803902 hasConcept C126322002 @default.
• W4285803902 hasConcept C188816634 @default.
• W4285803902 hasConcept C203014093 @default.
• W4285803902 hasConcept C534529494 @default.
• W4285803902 hasConcept C71924100 @default.
• W4285803902 hasConcept C85663871 @default.
• W4285803902 hasConcept C8891405 @default.
• W4285803902 hasConcept C90924648 @default.
• W4285803902 hasConceptScore W4285803902C126322002 @default.
• W4285803902 hasConceptScore W4285803902C188816634 @default.
• W4285803902 hasConceptScore W4285803902C203014093 @default.
• W4285803902 hasConceptScore W4285803902C534529494 @default.
• W4285803902 hasConceptScore W4285803902C71924100 @default.
• W4285803902 hasConceptScore W4285803902C85663871 @default.
• W4285803902 hasConceptScore W4285803902C8891405 @default.
• W4285803902 hasConceptScore W4285803902C90924648 @default.
• W4285803902 hasIssue "2" @default.
• W4285803902 hasLocation W42858039021 @default.
• W4285803902 hasOpenAccess W4285803902 @default.
• W4285803902 hasPrimaryLocation W42858039021 @default.
• W4285803902 hasRelatedWork W2002347000 @default.
• W4285803902 hasRelatedWork W2011632803 @default.
• W4285803902 hasRelatedWork W2056385328 @default.
• W4285803902 hasRelatedWork W2295722933 @default.
• W4285803902 hasRelatedWork W2411569915 @default.
• W4285803902 hasRelatedWork W2515762743 @default.
• W4285803902 hasRelatedWork W2531350361 @default.
• W4285803902 hasRelatedWork W2577548098 @default.
• W4285803902 hasRelatedWork W3031852375 @default.
• W4285803902 hasRelatedWork W3112940496 @default.
• W4285803902 hasVolume "21" @default.
• W4285803902 isParatext "false" @default.
• W4285803902 isRetracted "false" @default.
• W4285803902 workType "article" @default.